Fortress Biotech, Inc. (FBIO) Revenue History
Annual and quarterly revenue from 2009 to present
FBIO Revenue Over Time (2009–2025)
FBIO Revenue Growth History
8 of 10 years with positive growth- FY2009 revenue growth
- N/A
- FY2010 revenue growth
- N/A
- FY2011 revenue growth
- N/A
- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- N/A
- FY2014 revenue growth
- N/A
- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- +1809.6%
- FY2017 revenue growth
- +1038.3%
- FY2018 revenue growth
- -85.7%
- FY2019 revenue growth
- +36.3%
- FY2020 revenue growth
- +24.5%
- FY2021 revenue growth
- +50.9%
- FY2022 revenue growth
- +10.1%
- FY2023 revenue growth
- +11.6%
- FY2024 revenue growth
- -31.8%
- FY2025 revenue growth
- +9.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $16.0M | +22.1% |
| Q4 2025 | $16.1M | +6.3% |
| Q3 2025 | $17.6M | +20.5% |
| Q2 2025 | $16.4M | +10.2% |
| Q1 2025 | $13.1M | +0.8% |
| Q4 2024 | $15.1M | -24.2% |
| Q3 2024 | $14.6M | -57.9% |
| Q2 2024 | $14.9M | -14.3% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2024)
FBIO's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
FBIO Revenue Analysis (2009–2025)
Current Revenue & Growth
As of June 28, 2026, Fortress Biotech, Inc. (FBIO) generated trailing twelve-month (TTM) revenue of $66.2 million, reflecting exceptional growth of +22.1% year-over-year. The most recent quarter (Q1 2026) recorded $16.0 million in revenue, down 0.3% sequentially.
Historical Growth Trajectory
FBIO's 5-year compound annual growth rate (CAGR) stands at +6.8%, indicating steady revenue expansion. The 3-year CAGR of -5.8% is below the 5-year average, signalling a growth deceleration in recent years. Fortress Biotech, Inc.'s highest annual revenue of $187.6 million was recorded in 2017.
Revenue by Segment
FBIO's revenue is primarily driven by Qbrexza (49%), Accutane (38%), and Amzeeq (10%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including XOMA (-3.3% YoY), RCUS (+67.4% YoY), and ROIV (-67.7% YoY) — FBIO has outperformed the peer group in revenue growth. Compare FBIO vs XOMA →
FBIO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| FBIOCurrent | $66M | +22.1% | +6.8% | -111.0% | |
 XOMA | $52M | -3.3% | +12.2% | 21.8% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 ROIV | $8M | -67.7% | -19.1% | -15560.6% | |
 MNOV | $409,657 | - | - | -3242.5% |
FBIO Historical Revenue Data (2009–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $63.3M | +9.7% | $42.3M | 66.9% | $-70,221,000 | -111.0% |
| 2024 | $57.7M | -31.8% | $36.8M | 63.8% | $-110,379,000 | -191.4% |
| 2023 | $84.5M | +11.6% | $61.6M | 72.9% | $-142,342,000 | -168.4% |
| 2022 | $75.7M | +10.1% | $45.0M | 59.4% | $-203,564,000 | -268.8% |
| 2021 | $68.8M | +50.9% | $36.7M | 53.4% | $-188,541,000 | -274.1% |
| 2020 | $45.6M | +24.5% | $31.0M | 68.0% | $-94,270,000 | -206.7% |
| 2019 | $36.6M | +36.3% | $26.1M | 71.2% | $-110,819,000 | -302.5% |
| 2018 | $26.9M | -85.7% | $20.8M | 77.2% | $-119,997,000 | -446.4% |
| 2017 | $187.6M | +1038.3% | $26.4M | 14.1% | $-89,796,000 | -47.9% |
| 2016 | $16.5M | +1809.6% | $5.1M | 31.1% | $-65,710,000 | -398.7% |
| 2015 | $863K | - | $863K | 100.0% | $-50,531,000 | -5855.3% |
| 2014 | $0 | - | $0 | - | $-20,652,000 | - |
| 2013 | $0 | - | $0 | - | $-35,780,000 | - |
| 2012 | $0 | - | $0 | - | $-27,176,000 | - |
| 2011 | $0 | - | $0 | - | $-35,044,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
17+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
FBIO — Frequently Asked Questions
Quick answers to the most common questions about buying FBIO stock.
Is FBIO's revenue growth accelerating or slowing?
FBIO revenue growth is accelerating. TTM revenue reached $66M, up +22.1% year-over-year — ahead of the 5-year CAGR of +6.8%. This indicates the business is expanding faster than its historical baseline.
What is FBIO's revenue history from 2009 to 2026?
Fortress Biotech, Inc. (FBIO) revenue history spans 2009 to 2026. TTM revenue as of 2026 is $66M, growing at +22.1% YoY. The 5-year CAGR is +6.8%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is FBIO's long-term revenue growth rate (CAGR)?
Fortress Biotech, Inc.'s 5-year revenue CAGR of +6.8% reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +22.1% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for FBIO.
Why does FBIO's quarterly revenue fluctuate?
FBIO quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Fortress Biotech, Inc.'s revenue data from 2009 to 2026 shows full historical quarterly detail on this page.
How is FBIO's revenue distributed by segment?
FBIO reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does FBIO's revenue compare to industry peers?
Fortress Biotech, Inc. (FBIO) with TTM revenue of $66M and +22.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.